Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 767

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 767
---
     |             |            |   |     |                |            |   |
| Balance as of December 31, 2023 (Audited)                                                                                         |     |                                           | 510,000 |     | $      | 51 |     | $                      | 2,062,500 |     | $      | 206 |     | $           | (8,282,297 | ) |     | $              | (8,282,040 | ) |
| Net income                                                                                                                        |     |                                           |       — |     |        |  — |     |                        |         — |     |        |   — |     |             |    264,330 |   |     |                |    264,330 |   |
| Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) |     |                                           |       — |     |        |  — |     |                        |         — |     |        |   — |     |             |   (803,885 | ) |     |                |   (803,885 | ) |
| Balance as of March 31, 2024 (Unaudited)                                                                                          |     |                                           | 510,000 |     | $      | 51 |     | $                      | 2,062,500 |     | $      | 206 |     | $           | (8,821,852 | ) |     | $              | (8,821,595 | ) |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-36

DENALI CAPITAL ACQUISITION CORP. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

| Cash flows from operating activities:                                              |     | For theThree MonthsYear EndedMarch 31,2025 |          |   |     | For theThree MonthsYear EndedMarch 31,2024 |          |   |
|:-----------------------------------------------------------------------------------|:----|:-------------------------------------------|---------:|:--|:----|:-------------------------------------------|---------:|:--|
| Net income/loss                                                                    |     | $                                          | (194,603 | ) |     | $                                          |  264,330 |   |
| Formation costs paid by related party                                              |     |                                            |        — |   |     |                                            |        — |   |
| Adjustments to reconcile net loss to